


INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011
RECEIVED
 SEP 20 2002
 TECH CENTER 1600/2900

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm et al.		
Filing Date	October 12, 2000	Group:	1615



U.S. PATENT DOCUMENTS


Examiner Initial*	Document Number	Issue/ Publication Date	Name	Class	Sub Class	Filing Date If Appropriate
CB	4,950,484	Aug 21, 1990	Olthoff, et al.			
	5,051,262	Sep 24, 1991	Panoz, et al.			
	5,133,974	Jul 28, 1992	Paradissis, et al.			
	5,158,779	Oct 27, 1992	Gergely, et al.			
	5,407,686	Apr 18, 1995	Patel, et al.			
	5,445,829	Aug 29, 1995	Paradissis, et al.			
	5,487,901	Jan 30, 1996	Conte, et al.			
	5,500,227	Mar 19, 1996	Oshlack, et al.			
	5,650,169	Jul 22, 1997	Conte, et al.			
	5,670,170	Sep 23, 1997	Grimmett, et al.			
	5,681,583	Oct 28, 1997	Conte, et al.			
	5,738,874	Apr 14, 1998	Conte, et al.			
	5,741,524	Apr 21, 1998	Staniforth, et al.			
	5,849,330	Dec 15, 1998	Marvola, et al.			
	5,858,412	Jan 12 1999	Staniforth, et al.			
	6,126,969	Oct 3, 2000	Shah, et al.			
	US 6,177,421 B1	Jan 23, 2001	Moir, et al.			
	US 6,183,778 B1	Feb 6, 2001	Conte, et al.			
	US 6,183,780 B1	Feb 6, 2001	Van Balken, et al.			
	US 6,294,199 B1	Sep 25, 2001	Conley, et al.			
	US 6,294,200 B1	Sep 25, 2001	Conte, et al.			
	US 6,372,255 B1	Apr 16, 2002	Saslawski, et al.			
	US 2001/0018070A1	Aug 30, 2001	Shell, et al.			
	US 2001/0026809A1	Oct 4, 2001	Oshlack, et al.			
	US 2001/0038838A1	Nov 8, 2001	Burch			
	US 2001/0043926A1	Nov 22, 2001	Burch			
ES	US 2001/0046984A1	Nov 29, 2001	Rudnic			

INFORMATION DISCLOSURE CITATION

OMB No. 0654-0047

SEP 20 2002

Atty. Docket No. P32685	Appln. No. 09/689,483	TECH CENTER 1600/2900
Applicant Storm et al.		
Filing Date October 12, 2000	Group: 1615	



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue/ Publication Date	Name	Class	Sub Class	Filing Date If Appropriate
UB	US 2001/0048944A1	Dec 6, 2001	Rudnic, et al.			
	US 2002/0001616A1	Jan 3, 2002	Conley, et al.			
	US 2002/0004071A1	Jan 10, 2002	Cherukuri			
	US 2002/0004499A1	Jan 10, 2002	Rudnic, et al.			
UB	US 2002/0006433A1	Jan 17, 2002	Davidson, et al.			

FOREIGN PATENT DOCUMENTS


Examiner Initial*	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
UB	EP 0131147 B1	Jan 16, 1985	EPO			
	EP 0131147 B2	Dec 12, 1996	EPO			
	EP 0222914 A1	May 27, 1987	EPO			
	EP 0396335 A1	Nov 7, 1990	EPO			
	WO 94/06416	Mar 31, 1994	PCTWIPO			
	WO 98/05305	Feb 12, 1998	PCTWIPO			
	WO 98/22091	May 28, 1998	PCTWIPO			
	WO 99/25343	May 27, 1999	PCTWIPO			
	WO 99/47125	Sep 23 1999	PCTWIPO			
	WO 99/62910	Dec 9, 1999	PCTWIPO			
	WO 00/23045	Apr 27, 2000	PCTWIPO			English abstract
	WO 00/41478	Jul 20, 2000	PCTWIPO			
	WO 00/44353	Aug 3, 2000	PCTWIPO			English Abstract
	WO 00/61116	Oct 19, 2000	PCTWIPO			
	WO 01/00177 A1	Jan 4, 2001	PCTWIPO			
	WO 01/56544 A2	Aug 9, 2001	PCTWIPO			
	WO 01/62231 A1	Aug 30, 2001	PCTWIPO			
UB	WO 01/80824 A2	Nov 1, 2001	PCTWIPO			

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011
RECEIVED

SEP 20 2002

Atty. Docket No. P32685	Appln. No. 09/689,483
Applicant Storm et al.	TECH CENTER 1600/2900
Filing Date October 12, 2000	Group: 1615



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PS	Appelbaum, 1996, "Epidemiology and <i>in vitro</i> susceptibility of drug-resistant <i>Streptococcus pneumoniae</i> ," <i>Ped. Inf. Dis. J.</i> , 15(10): 932-939.
	Arancibia et al., 1987, "Pharmacokinetics and bioavailability of a controlled release amoxicillin formulation," <i>Int. J. of Clin. Pharm., Ther. and Tox.</i> , 25(2): 97-100.
	Bronner et al., 2001, "Ex vivo pharmacodynamics of amoxicillin-clavulanic acid 1.1gr IV against strains of -lactamase producing <i>E. coli</i> in an experimental model of Yucatan micropig that mimics human pharmacokinetics (2.2 g IV)," <i>Antibiotiques</i> , 2001, 3: 91-98.
	Cars, 1997, "Efficiency of Beta-lactam Antibiotics," <i>Diagn. Microbiol. Infect. Dis.</i> , 27: 29-33.
	Chiou, "Critical Evaluation of the Potential Error in Pharmacokinetic Studies of Using the Linear Trapezoidal Rule Method for the Calculation of the Area Under the Plasma Level-Time Curve," 1978, <i>J. Pharmicokinet. Biopharm.</i> , 6: 539-547.
	Craig, 1998, "Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men," <i>Clinical Infectious Diseases</i> , 26: 1-12.
	Hilton et al., 1992, "In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate," <i>Intl. J. of Pharmaceutics</i> , 86: 79-88.
	Hilton et al., 1993, "Use of Hydroxypropyl Methylcellulose Acetate Succinate in an Enteric Polymer Matrix to Design Controlled-Release Tablets of Amoxicillin Trihydrate," <i>J. Pharmaceutical Sciences</i> , 82(7): 737-743.
	Hoffman, et al., 1998, "Pharmacodynamic and Pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form," <i>J. Controlled Release</i> , 54: 29-37.
	The Merck Index, 11 th Ed., Merck & Co., Inc., Rahway, NJ, 1989, p 2342-2343.
	Nicolau et al., 1995, "Antibiotic Kinetics and Dynamics for the Clinician," <i>Antimicrobial Therapy</i> 1, 79(3): 477-495.
	Physicians' Desk Reference, 1998, 52 nd Edition, Medical Economics Co., Montvale, NJ, p. 2798-2805.
PS	Woodnutt et al., 1995, "Evaluation of reduced dosing schedule of amoxicillin (AMX) using two pharmacodynamic models," Abstracts of the 36 th Interscience Conference on Antimicrobial Agents and Chemotherapy, A40.

Examiner Rachel Beut	Date Considered 2/14/03
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	